Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

MorphoSys to Present at Two Upcoming Investor Conferences


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-03-04 16:03:15 -

MorphoSys AG /
MorphoSys to Present at Two Upcoming Investor Conferences
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
management will present at two upcoming international investor conferences:


Credit Suisse Global Healthcare One-on-One Conference
Date: March 6, 2013
Venue: London, UK
Participants: Jens Holstein, Chief Financial Officer; Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations

Barclays Global Healthcare Conference in Miami, FL, USA
Date: March 14, 2013, 9:00 am EDT (1:00 pm GMT, 2:00 pm CET)
Venue: Miami, FL, USA
Participants: Jens Holstein, Chief Financial Officer; Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations


The  PDF version of the presentations will be provided at www.morphosys.com. The
link to the webcast will be filed under 
www.morphosys.com/conference-calls. About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com. HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®), Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of MorphoSys AG. Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 Mario Brkulj Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 Alexandra Goller Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-332 investors@morphosys.com Media Release (PDF): hugin.info/130295/R/1682744/550542.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: MorphoSys AG via Thomson Reuters ONE [HUG#1682744]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser